Evidence map›Paper›PMID 41625892›Full record

ArticleCureus2025

Diagnostic Value of Serum Procalcitonin and Erythrocyte-bound Complement Component 4d (E-C4d) Levels in Differentiating a Flare-up from a Bacterial Infection in Egyptian Patients with Systemic Lupus Erythematosus.

Mona A Abd El-Hamid, Niveen A Elwakeel, Medhat M Ali, Sherif R El-Basiouny, Ghada M Elnady

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mona A Abd El-HamidMedical Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, EGY.
Niveen A ElwakeelMedical Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, EGY.
Medhat M AliMedical Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, EGY.
Sherif R El-BasiounyRheumatology and Rehabilitation, Faculty of Medicine, Mansoura University, Mansoura, EGY.
Ghada M ElnadyMedical Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, EGY.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The distinction between bacterial infection and febrile flare in patients with systemic lupus erythematosus (SLE) has always been a crucial yet difficult step in the management of these patients. Although the presentation looks similar, the treatment is extremely different and increases the burden on health care systems, particularly in low-income countries. Aim of this study This study aimed to investigate the potential value of combining serum procalcitonin (PCT) and erythrocyte-bound Complement Component 4d (E-C4d) measurements in distinguishing infection from disease flare in patients with SLE. Methods Serum levels of these two biomarkers were analyzed in patients with positive aerobic bacterial cultures, patients with flare-up fever showing no signs of infection, and a control group with medical diseases other than SLE. Results The PCT level was found to be high in patients with bacterial infections and is considered a suitable marker to exclude cases of SLE with bacterial infections. Additionally, E-C4d was found to have a positive correlation with SLE flare-ups. Conclusion Our findings suggest that the use of serum PCT and E-C4d simultaneously may help differentiate between lupus flares and bacterial infection. However, this observation needs further validation in larger studies.

Indexed as

bacterial infectione-c4derythrocyte-bound complement component 4d (e-c4d)flareprocalcitoninsystemic lupus erythematosus

Identifiers

PMID41625892
PMCPMC12856363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.